Immuron (IMRN) EBIT (2016 - 2024)
Immuron's quarterly EBIT came in at $1660259127.7 billion in Q4 2024, up 82189906661311.72% year-on-year from N/an in Q1 2024, and up 82189906661311.72% quarter-over-quarter from -$2.0 million in Q4 2023.
Immuron has reported EBIT for 9 years, with the latest figure at $1660259127.7 billion in Q4 2024.
- For the quarter ending Q4 2024, EBIT rose 82189906661311.72% year-over-year to $1660259127.7 billion; the trailing twelve-month figure through Dec 2024 stood at $1660259127.7 billion (up 12515523057.22% YoY), and the FY2025 full-year result was -$3.5 million, up 8.95% from the prior year.
- EBIT for Q4 2024 stood at $1660259127.7 billion, up from -$2.0 million in the prior quarter.
- The five-year high for EBIT was $1660259127.7 billion in Q4 2024, with the low at -$13.3 billion in Q4 2021.
- Average EBIT over 5 years is $276709852.4 billion, with a median of -$648609.5 recorded in 2023.
- Year-over-year, EBIT slumped 23116432.23% in 2021 and soared 82189906661311.72% in 2024.
- Tracing IMRN's EBIT over 5 years: stood at -$57371.6 in 2020, then tumbled by 23116432.23% to -$13.3 billion in 2021, then surged by 100.0% to -$12721.4 in 2022, then plunged by 15779.01% to -$2.0 million in 2023, then soared by 82189906661311.72% to $1660259127.7 billion in 2024.
- The last three EBIT figures came in at $1660259127.7 billion (Q4 2024), -$2.0 million (Q4 2023), and -$1.2 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1,660,259,127.73 Bn |
| Dec 31, 2023 | -2.02 Mn |
| Jun 30, 2023 | -1.24 Mn |
| Dec 31, 2022 | -12,721.37 |
| Dec 31, 2021 | -13.26 Bn |
| Dec 31, 2020 | -57,371.61 |
| Dec 31, 2019 | -15,191.40 |
| Dec 31, 2018 | -1.58 Mn |
| Dec 31, 2017 | 3.84 Mn |
| Dec 31, 2016 | 2.56 Mn |
| Jun 30, 2016 | 4.33 Mn |